Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Key Inclusion Criteria: * Relapsed/refractory, pathologically confirmed Epstein-Barr Virus positive (EBV+) lymphoid malignancy or lymphoproliferative disease * Absence of available therapy with reasonable likelihood of cure or significant clinical benefit * Adequate hematologic, hepatic and renal function as defined by laboratory assessment Key Exclusion Criteria: * Known primary central nervous system (CNS) lymphoma * Known CNS metastases or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks * Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy * Refractory graft versus host disease (GvHD) not responding to treatment * Known active hepatitis B virus infection * Circulating hepatitis C virus on quantitative polymerase chain reaction (qPCR) * Known history of human herpes virus (HHV)-6 chromosomal integration * Known history of HIV infection